Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

por Pili, R, Salumbides, B, Zhao, M, Altiok, S, Qian, D, Zwiebel, J, Carducci, M A, Rudek, M A
Publicado 2012

A phase 1 study assessing the feasibility and safety of intraductal pegylated liposomal doxorubicin (PLD) in women awaiting mastectomy

por Stearns, V, Jacobs, L, Khouri, N, Jeter, S, Powers, P, Shahverdi, K, Brown, R, Rudek, M, Gabrielson, E, Zhang, Z, Tsangaris, T, Sukumar, S
Publicado 2009

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours

por Wilky, B A, Rudek, M A, Ahmed, S, Laheru, D A, Cosgrove, D, Donehower, R C, Nelkin, B, Ball, D, Doyle, L A, Chen, H, Ye, X, Bigley, G, Womack, C, Azad, N S
Publicado 2015

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs

por Overbeek, J.K., Heine, R. ter, Verheul, H.M.W., Chatelut, E., Rudek, M.A., Gurney, H., Plummer, R., Gilbert, D.C., Buclin, T., Burger, D.M., Bloemendal, H.J., van Erp, N.P.
Publicado 2023

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer

por Garrido-Laguna, I, Tan, A C, Uson, M, Angenendt, M, Ma, W W, Villaroel, M C, Zhao, M, Rajeshkumar, N V, Jimeno, A, Donehower, R, Iacobuzio-Donahue, C, Barrett, M, Rudek, M A, Rubio-Viqueira, B, Laheru, D, Hidalgo, M
Publicado 2010